Jorge Duconge to Pharmacogenetics
This is a "connection" page, showing publications Jorge Duconge has written about Pharmacogenetics.
Connection Strength
4.488
-
Mart?nez-Jim?nez JE, Ortega-Lamp?n Y, Cedres-Rivera D, Heredia-Negr?n F, Roche-Lima A, Duconge J. Leveraging Machine Learning to Predict Warfarin Sensitivity in the Puerto Rican Population: A Pharmacogenomic Approach. Int J Environ Res Public Health. 2026 Mar 07; 23(3).
Score: 0.933
-
Duconge J, Santiago E, Hernandez-Suarez DF, Moner? M, L?pez-Reyes A, Rosario M, Renta JY, Gonz?lez P, Ileana Fern?ndez-Morales L, Antonio V?lez-Figueroa L, Arce O, Mar?n-Maldonado F, Nu?ez H, Melin K, Scott SA, Rua?o G. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clin Transl Sci. 2021 11; 14(6):2254-2266.
Score: 0.681
-
Duconge J, Rua?o G. Admixture and ethno-specific alleles: missing links for global pharmacogenomics. Pharmacogenomics. 2016 09; 17(14):1479-82.
Score: 0.481
-
Duconge J, Rua?o G. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics. 2015; 16(15):1685-8.
Score: 0.453
-
Nu?ez-Medina HJ, Monero M, Torres LM, Leal E, Gonzalez-Sepulveda L, Mayor ?M, Renta JY, Gonz?lez-Garc?a ER, Gonz?lez A, Melin K, Scott SA, Rua?o G, Hernandez-Suarez DF, Duconge J. Implementing a pharmacogenomic-driven algorithm to guide antiplatelet therapy among Caribbean Hispanics: a non-randomised clinical trial. BMJ Open. 2024 09 05; 14(9):e084119.
Score: 0.210
-
Hernandez-Martinez V, Duconge J, Rua?o G. An Expiration Date for Pharmacogenetic Test Results and Prescribing Guidance? J Appl Lab Med. 2023 07 05; 8(4):826-830.
Score: 0.194
-
Hernandez-Suarez DF, Melin K, Marin-Maldonado F, Nunez HJ, Gonzalez AF, Gonzalez-Sepulveda L, Rivas-Tumanyan S, Naik H, Rua?o G, Scott SA, Duconge J. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open. 2020 08 06; 10(8):e038936.
Score: 0.158
-
Claudio-Campos K, Moner?-Paredes M, Hern?ndez E, Renta J, Duconge J. Low-frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation. Pharmacogenomics. 2019 08; 20(12):891-902.
Score: 0.148
-
Claudio-Campos KI, Gonz?lez-Santiago P, Renta JY, Rodr?guez J, Carrasquillo K, Gaedigk A, Roche A, Ducong? J. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics. 2019 01; 20(1):3-8.
Score: 0.141
-
Duconge J, Rua?o G. Preventing the exacerbation of health disparities by iatrogenic pharmacogenomic applications: lessons from warfarin. Pharmacogenomics. 2018 07 01; 19(11):875-881.
Score: 0.136
-
Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nu?ez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int J Environ Res Public Health. 2018 05 30; 15(6).
Score: 0.136
-
Duconge J, Hernandez-Suarez DF. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. Curr Clin Pharmacol. 2017; 12(1):11-17.
Score: 0.123
-
C?spedes-Garro C, Naranjo MG, Rodrigues-Soares F, LLerena A, Duconge J, Montan?-Jaime LK, Roblejo H, Fari?as H, Campos ML, Ram?rez R, Serrano V, Villagr?n CI, Pe?as-LLed? EM. Pharmacogenetic research activity in Central America and the Caribbean: a systematic review. Pharmacogenomics. 2016 10; 17(15):1707-1724.
Score: 0.121
-
Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, Garc?a R, Hern?ndez G, Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metab Pers Ther. 2015 Dec; 30(4):239-49.
Score: 0.114
-
Duconge J, Rua?o G. 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics. 2012 Jul; 13(10):1097-100.
Score: 0.090
-
Villagra D, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Rua?o G. CYP2C9 and VKORC1 genotypes in Puerto Ricans: A case for admixture-matching in clinical pharmacogenetic studies. Clin Chim Acta. 2010 Sep 06; 411(17-18):1306-11.
Score: 0.078
-
Seip RL, Duconge J, Rua?o G. Implementing genotype-guided antithrombotic therapy. Future Cardiol. 2010 May; 6(3):409-24.
Score: 0.078
-
Rua?o G, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Villagra D, Renta J, Holford T, Santiago-Borrero PJ. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics. 2009 Apr; 10(4):565-77.
Score: 0.072
-
Zubiaur P, Rodr?guez-Antona C, Boone EC, Daly AK, Tsermpini EE, Khasawneh LQ, Sangkuhl K, Duconge J, Botton MR, Savieo J, Nofziger C, Whirl-Carrillo M, Klein TE, Gaedigk A. PharmVar GeneFocus: CYP4F2. Clin Pharmacol Ther. 2024 Oct; 116(4):963-975.
Score: 0.052
-
Morales-Borges RH, Gonzalez MJ, Duconge J, Minich DM. N-Acetyl Cysteine and Glutathione in Health and Cancer-Pharmacogenomics, Research, and Clinical Practice: Hypothesis and Review. Altern Ther Health Med. 2022 Oct; 28(7):169-177.
Score: 0.046
-
Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Rodrigues Botton M, Woodahl EL, Scott SA, Klein TE, Pratt VM, Daly AK, Gaedigk A. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 2021 09; 110(3):662-676.
Score: 0.042